SCHEMBL4667470

SCHEMBL4667470

O=CON(c1ccc(Nc2cc(-c3ccc4c(ccn4CCN4CCCC4)c3)ncn2)cc1)S(=O)(=O)c1c(F)cccc1F

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 12/20 0.36
BCR P11274 12/20 0.36
HTR6 P50406 4/20 0.35
EGFR P00533 3/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
GLA P06280 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
ALOX15 P16050 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4667365 0.96 HTR6 (0.35) ABL1BCRHTR6EGFRMEN1
SCHEMBL4666171 0.95 ABL1 (0.36) ABL1BCREGFRMEN1USP2
SCHEMBL4667510 0.93 HTR6 (0.37) ABL1BCRHTR6EGFRMEN1
SCHEMBL4666137 0.91 ABL1 (0.35) ABL1BCREGFRMEN1USP2
SCHEMBL4663898 0.90 EGFR (0.37) ABL1BCRHTR6EGFRMEN1
SCHEMBL4666161 0.89 ABL1 (0.36) ABL1BCRHTR6MEN1USP2
SCHEMBL4664038 0.89 EGFR (0.35) ABL1BCRHTR6EGFRMEN1
SCHEMBL4665757 0.88 HTR6 (0.35) ABL1BCRHTR6EGFRMEN1
SCHEMBL4664278 0.88 ABL1 (0.35) ABL1BCREGFRMEN1USP2
SCHEMBL4665713 0.88 ABL1 (0.37) ABL1BCREGFRMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 ABL1 24/4885BCR 402/4885HTR6 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.